Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.65 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915791 | 0.83 | IDO1 (0.81) | IDO1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL19915651 | 0.82 | IDO1 (0.73) | IDO1FNTAFNTBPGGT1BRORC | |
| SCHEMBL29561614 | 0.79 | IDO1 (1.00) | IDO1 | |
| SCHEMBL19915650 | 0.79 | IDO1 (1.00) | IDO1 | |
| SCHEMBL19915738 | 0.78 | IDO1 (0.68) | IDO1CACNA1HCYP11B1CYP11B2RORC | |
| SCHEMBL19915785 | 0.76 | IDO1 (0.75) | IDO1CYP11B1CYP11B2 | |
| SCHEMBL19915731 | 0.75 | IDO1 (1.00) | IDO1FNTAFNTBPGGT1B | |
| SCHEMBL19915732 | 0.74 | IDO1 (0.78) | IDO1 | |
| SCHEMBL19915730 | 0.74 | IDO1 (0.78) | IDO1CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL19915654 | 0.74 | IDO1 (0.66) | IDO1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689652-B | Fused heterocyclic derivative, preparation method and medical application thereof | 北京诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| WO-2018036414-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 北京诺诚健华医药科技有限公司 | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | IDO1, IDO2, INMT | IDO1 1/4885CACNA1H 4294/4885CYP11B1 55/4885 |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | IDO1, IDO2, INMT | IDO1 1/4885CACNA1H 4294/4885CYP11B1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.